Boehringer Ingelheim has always believed the biggest opportunity for its dual glucagon/GLP-1 receptor agonist candidate survodutide lay in treating metabolic dysfunction-associated steatohepatitis (MASH) and new Phase II data look to support this premise.
Key Takeaways
-
83% of trial participants achieved an improvement of MASH – one of the most impressive results in the field
Just-released topline data show 83% of adults treated with a once-weekly injection achieved a statistically significant improvement of MASH versus...
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
